ST36 acupoint injections with dexamethasone outperforms conventional western medicine in treating chemotherapy-induced myelosuppression, significantly improving clinical efficacy and recovery.
Systematic Review ST36
The study executed a systematic evaluation of the efficacy of ST36 acupoint injection with dexamethasone in treating chemotherapy-induced myelosuppression. A total of 17 randomized controlled trials from eight different databases were extracted for this meta-analysis. A detailed examination and analysis of various data gathered were performed using the Cochrane Collaboration tool for bias, Excel 2010 for creating an information extraction database, and RevMan 5.3.0 software for analyzing test data. The quality of evidence was graded using GRADE profiler 3.6 software.
The results indicated that compared to conventional western medicine, ST36 acupoint injection with dexamethasone vastly improved the clinical aggregate effective rate. Notably, it increased the white blood cell count and hemoglobin levels in patients, further enhancing their Karnofsky performance status. The treatment also shortened the recovery time of myelosuppression. However, there were no significant differences observed in platelet elevation between the ST36 acupoint injection with dexamethasone and conventional western medicine.
View Article